Mitsubishi Tanabe Pharma’s twice-yearly neuromyelitis optica spectrum disorder (NMOSD) drug Uplizna is headed for reimbursement listing in Korea.

According to industry sources, Mitsubishi Tanabe Pharma’s Korea accepted the ‘below the evaluated amount’ condition set by the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee for the reimbursement of Uplizna (inebilizumab), a treatment used to treat adult patients with for neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-Aquaporin-4 (AQP4) antibodies.

As a result, the company will enter pricing negotiations with the National Health Insurance Service in the near future. Uplizna